Quantum-Si Reports 69.4% Revenue Decline and Increased Net Loss in Q1 2026

Quantum-Si Incorporated reported its financial results for the first quarter of 2026, revealing a significant decline in revenue and an increase in net loss compared to the same period in 2025. The company generated total revenue of $258,000, a decrease of 69.4% from $842,000 in the prior year. This decline was primarily attributed to a 73.3% drop in product revenue, which fell to $216,000 from $808,000, as customers deferred purchases in anticipation of the upcoming launch of the Proteus platform. Service revenue, however, increased by 23.5% to $42,000, up from $34,000.

The company's net loss for the quarter was $21.7 million, compared to a loss of $19.2 million in the same quarter of 2025, marking a 12.9% increase in losses. The loss per share was reported at $0.10, slightly improved from $0.11 in the previous year. Operating expenses decreased by 5.7% to $24.1 million, driven by a reduction in selling, general, and administrative expenses, which fell by 18.9% to $9.6 million. Research and development expenses, however, increased by 5.6% to $14.5 million, reflecting ongoing investments in product development.

In terms of operational metrics, Quantum-Si's cash and cash equivalents, along with investments in marketable securities, totaled $190.4 million as of March 31, 2026. This represents a significant increase from $175.9 million at the end of 2025, bolstered by cash inflows from the sale and maturity of marketable securities. The company reported a net cash inflow of $40.3 million from investing activities during the quarter, primarily due to $104.7 million in proceeds from sales and maturities of marketable securities.

Looking ahead, Quantum-Si anticipates that the launch of its Proteus platform, expected by the end of 2026, will significantly impact its revenue generation. However, the company cautioned that customer purchasing decisions may continue to be delayed until the new product is available. Management believes that the current cash reserves, combined with anticipated revenue from product sales, will be sufficient to fund operations for at least the next twelve months. The company continues to explore additional financing options to support its ongoing research and development efforts and operational needs.